Obesity is a chronic disease that is increasing in prevalence and represents an important risk factor for the developement of diabetes, heart disease, hypertension and many forms of cancer. Fat distribution has a profound influence on health risks. For example, increased deposits of visceral, or abdominal fat correlate with risks for many diseases. The leptin system is an important and essential regulating factor for body weight and developement. Many studies have demonstrated that leptin plays an important role in behavior disorders such as obesity and anorexia. In recent studies insulin resistance has received considerable attention in the development of the metabolic syndrome, a cluster of disorders comprising glucose intolerance, dyslipidemia, hypertension, and dysfibrinolysis that is associated with type-Z diabetes and cardiovascular disease. The aim of this short review is to define the interaction between leptin, obesity and insulin dependent diabetes mellitus.
Obesity
Obesity (0) is defined as the increase of corporal fat, and represents a serious health problem in all western societies, not only of people born in the West, but even of immigrants of all races. It represented a serious risk factor for the development of diabetes mellitus, hypertension, hearth disease, gall bladder disease and many forms of cancer. The method more commonly accepted to measure corporal fat is the body mass index (BMI), obtained by dividing the weight in kilograms (Kg) to the stature in metres (m) to the square (Kg/m-). A BMI between 20 and 25 is usually considered a good weight for most individuals. Overweight is defined as a BMI above 27 Kg/m/, and 0 is defined as a BMI above 30 Kg/m 2 (1-2).
In the last decade many studies emphasized the importance of genetic factors involved in the development of 0, in addition to environmental factors which interact with genetic susceptibility. For example, hypothalamic injury from trauma or surgery and destructive lesions in the region of the ventromedial or the paraventricular nucleus can produce 0 for the increase in parasympathetic and reduced sympathetic nervous system activity. The sequence of this event may be the altered secretion of neuropeptide Y (NPY), produced in the arcuate nucleus and acts in the hypothalamus to stimulate eating. (3) .
Leptin
Leptin (L) is a 167 amino-acid protein synthesized and secreted by adipocytes which provides a feedback signal from adipose tissue to receptors in the hypothalamus. Visceral adipocytes appear to produce less L than their subcutaneous counterpart (4) (5) . L crosses the blood-brain barrier to inhibit the synthesis of NPY with powerful stimulatory effects on appetite. It also inhibits other orexigenic neuropeptides (6) . High L levels are indicative of an excessive adipose tissue mass which lead to increased thermogenesis (NPY, also inhibits the activity of thermogenic brown adipose tissue in the rat). Concomitantly, NPY administration increases the activity of the hypothalamuspituitary-adrenal axis, with resulting hypercortisolemia and increased susceptibility to stressful situations. These effects serve to limit further weight gain (7) (8) . Animal models in which L (ob/ob mouse), or its hypothalamic receptor (db/ db mouse, fa/fa rat) are absent are associated with o and insulin resistance (lR). These models have been used as genetic models for O. The study of its genotypes and the c1onation of some of its genes have changed the concept of the adipocyte from "organ" of energetic reserve to "organ" secretory of some hormones among them L (9) . Circulating L concentrations are elevated in most obese humans implying cellular resistance rather than deficiency (10) (11) . Plasma L concentrations correlate with hyperinsulinemia independently of BM!. Another study has identified a mechanism that helps explain how the hormone L acts to metabolize fatty acids in muscle, establishing for the first time a novel molecular link between 0 and diabetes, and creating the possibility of a new target for the development of drugs to help manage both conditions (12) .
Obesity and insulin resistance
o is associated with IR, particularly when body fat has a central distribution. However, IR also frequently occurs in apparently lean individuals. It has been proposed that these lean insulin-resistant individuals have greater amounts of body fat than lean insulin-sensitive subjects. Thus, accumulation of intra-abdominal fat (lAF) correlates with IR, whereas subcutaneous fat deposition (SFD) correlates with circulating L levels. The role of insulin resistance in metabolic diseases has received considerable attention in recent years (13) .
IR has been suggested to be an important risk factor in the development of the metabolic syndrome, a cluster of disorders comprising glucose intolerance, dyslipidemia, hypertension, and dysfibrinolysis that is associated with type 2 diabetes and cardiovascular disease (14) . It is evident that obesity is a risk factor for these same conditions and that this association is not only related to the degree of obesity, but also appears to be critically dependent on body fat distribution. Thus, individuals with greater degrees of central adiposity appear to develop this syndrome more frequently than those with a peripheral body fat distribution (15) (16) . Some studies have suggested that the IAF depot is the major determinant of IR (17 -I 9) and of other features of the metabolic syndrome (20-21), whereas others have suggested that the SCF compartment is the most critical determinant of insulin sensitivity (22-23).
IR also frequently occurs in apparently lean individuals (24). Because these lean insulin-resistant subjects have had a slightly greater BMI (24) or calculated fat mass (25), it has been suggested that they may be more obese than lean insulin-sensitive individuals (26). Body adiposity has been shown to be a major determinant of circulating L (27).
IAF is the major predictor of insulin sensitivity is in agreement with previous studies in 9 (18) and 16 men (19), in 25 black and whi te obese women (28) , and in 55 postmenopausal women (19). It has been proposed that IAF is only associated with IR in the setting of 0 because indexes of glucose intolerance and dyslipidemia correlated with IAF in obese subjects but not in lean subjects (29) .
Abate et al. suggested that SCF is the major determinant of insulin sensitivity in obese men, whereas intra-and retroperitoneal fat have a lesser role (22). They also studied type 2 diabetic patients and found that they were more insulin resistant and had more SCF but similar IAF than nondiabetic control subjects.
Goodpaster et al. found that total abdominal fat was strongly correlated with the insulin-stimulated glucose disposal rate but that IAF was not as good a predictor of insulin sensitivity as SCF in obese subjects, whereas in lean subjects, no correlations were detected (23).
In contrast, an interventional study of dietinduced weight loss, by the same group, showed that the improvement in insulin sensitivity correlated with the decrease in IAF but not with other measures of body composition (30) .
The apparent contradiction between these reports may possibly be explained by the nonlinearity of the IAF/insulin sensitivity relationship (apparent in the study by Goodpaster et al. (23) and also in a rodent model of visceral fat accumulation and IR (3 I). However, others have found that leptin levels correlate better with the size of the IAF depot than with SCF in men (32) .
Mechansim of insulin resistance
The mechanism by which IAF causes IR is not clear. It has been suggested that elevated free fatty acid concentrations are involved in the association between IAF and IR.
IAF is relatively insensitive to insulin (28, 33) and has ahigh lipolytic activity (28, 34) . In addition, subcutaneous adipocytes from women with visceral obesity exhibit higher lipolysis rates than those obtained from women with little visceral fat (35) . The increased plasma free fatty acid concentrations associated with intra-abdominal adiposity may induce fat accumulation and insulin insensitivity in skeletal muscle (36, 37) and liver (38) (39) (40) . It remains to be determined whether enlargement of the IAF depot is causally related to the triglyceride accumulation in liver and muscle or whether it is a marker of the process of fat deposition in these and other nonadipose tissues. Other adipocyte-derived proteins may also playa role in the pathogenesis of insulin resistance.
CONCLUSIONS
Leptin, a circulating hormone produced by lipid cells and initially discovered in mice, has become known as the "obesity hormone," for deficiencies are associated with obesity. A recent study followed both lean and obese human subjects given exogenous synthetic leptin via daily subcutaneous injection for a period of 6 months. Weight loss among patients receiving leptin as opposed to placebo were impressive. Though leptin has not yet been studied in patients with diabetes, weight loss almost invariably leads to reductions in blood glucose levels and facilitates maintenance of tighter control; so it holds great promise in these patients, who typically must choose between tight control to reduce risks of microvascular complications and minimizing obesity. 
